Sector: Health Care
Director information for ROYALTY PHARMA PLC CLASS A (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Bonnie Bassler | 63 | ["Leadership","Science / Biotech","Business Strategy","Research / Academic","Technology/Cybersecurity","Corporate Responsibility"] | [] | 2026 | |
| Bonnie Bassler, Ph.D. | Director | 63 | ["Chair, Department of Molecular Biology at Princeton University","Professor in the Department of Molecular Biology since 1994","Associated faculty member of the Department of Chemistry since 2010","Investigator at the Howard Hughes Medical Institute since 2005","Associate faculty member of the Princeton Environmental Institute since 1996","Director of the Council on Science and Technology at Princeton University from July 2008 to June 2013","Trustee of the Alfred P. Sloan Foundation since 2014","Board member of the American Association for the Advancement of Science from January 2012 to December 2016","Member of the National Science Board from January 2010 until May 2016","Elected to the National Academy of Sciences, the National Academy of Medicine, and the Royal Society"] | ["Management Development and Compensation Committee"] | 2026 |
| Carole Ho | 53 | ["Leadership","Science / Biotech","Corporate Responsibility"] | [] | 2026 | |
| Carole Ho, M.D. | EVP and President, Lilly Neuroscience; Independent Director | 53 | ["Executive Vice President and President, Lilly Neuroscience since December 2025","Chief Medical Officer and Head of Development of Denali Therapeutics from June 2015 to November 2025","Various roles at Genentech from 2007 to 2015","Associate Medical Director at Johnson & Johnson from November 2006 to October 2007","Instructor in the Department of Neurology and Neurological Sciences at Stanford University from June 2002 to November 2006","Board certified in neurology and psychiatry between 2004 and 2014","M.D. from Cornell University","B.S. in Biochemical Sciences from Harvard College"] | ["Nominating and Corporate Governance Committee"] | 2026 |
| Catherine Engelbert | Independent Director | 61 | ["Commissioner, Women’s National Basketball Association","Leadership","Business Strategy","Technology/Cybersecurity","Public Company CEO","FIRST Commissioner of the Women’s National Basketball Association since July 2019","Former CEO of Deloitte from 2014 to 2019","Experience in global business operations, finance, leadership, strategy and risk management","Certified Public Accountant","Audit committee financial expert","financial expert","audit committee experience"] | ["Audit Committee"] | 2026 |
| Christopher Hite | Executive Vice President & Vice Chairman; Executive Vice President & Vice-Chairman | 59 | ["Vice Chairman and Global Head of Healthcare at Citibank","Global Head of Healthcare Investment Banking at Lehman Brothers","Director of Acceleron Pharma Inc.","B.S. from Lehigh University","J.D./M.B.A. from the University of Pittsburgh"] | [] | 2026 |
| David Hodgson | Vice Chairman; Independent Director | 69 | ["Vice Chairman, General Atlantic","Leadership","Finance / Accounting","Business Strategy","Corporate Responsibility","Managing Director and Vice Chairman of General Atlantic","Board member of Johns Hopkins HealthCare and Johns Hopkins Medicine International","A.B. in Mathematics and Social Sciences from Dartmouth College","M.B.A. from the Stanford University Graduate School of Business","Extensive management and board experience","Knowledge of business, finance, and strategic transactions","Experience on other healthcare companies’ boards","financial expert","audit committee experience"] | ["Management Development and Compensation Committee (Chair)","Audit Committee (Member)","Audit Committee"] | 2026 |
| Elizabeth Weatherman | Independent Director | 66 | ["Special Limited Partner of Warburg Pincus LLC","Leadership","Science / Biotech","Business Strategy","Technology/Cybersecurity","Corporate Responsibility","30 years at Warburg Pincus","extensive knowledge of business, finance and strategic transactions","experience from other healthcare companies’ boards"] | ["Management Development and Compensation Committee"] | 2026 |
| Errol De Souza, Ph.D. | [] | ["Nominating and Corporate Governance Committee"] | 2026 | ||
| Gregory Norden | Independent Director; Chair | 68 | ["Former CFO, Wyeth","Leadership","Finance / Accounting","Business Strategy","Technology/Cybersecurity","Risk Management","Managing Director of G9 Capital Group LLC since January 2010","Member of the Investment Committee of Royalty Pharma (2014 to June 2020)","Various senior positions at Wyeth, including Chief Financial Officer from 1989 to 2010","Started career with Arthur Andersen & Company","Chair of Audit Committee","Selected for vast financial and accounting expertise","Broad knowledge of global business operations, finance, leadership, strategy and risk management","Qualified as an audit committee financial expert","financial expert","audit committee experience"] | ["Audit Committee","Nominating and Corporate Governance Committee"] | 2026 |
| Pablo Legorreta | Chairman and CEO; Chairman and Chief Executive Officer; Chairman of the Board and Chief Executive Officer | 62 | ["Chairman and CEO, Royalty Pharma plc","Leadership","Science / Biotech","Business Strategy","Risk Management","Corporate Responsibility","Public Company CEO","Chief Executive Officer and Chairman of the Board since inception","Former investment banker at Lazard Frères in Paris and New York","Co-founder of Pharmakon Advisors","Over 25 years of leadership experience","Demonstrated track record for delivering strong business results","Deep knowledge of investing in biopharma","Experience in the biopharmaceutical industry"] | [] | 2026 |
| Ted Love | 67 | ["Leadership","Finance / Accounting","Science / Biotech","Business Strategy","Technology/Cybersecurity","Risk Management","Corporate Responsibility","Public Company CEO","Promotes a strong Board culture","Presides over Board meetings","Leads executive sessions","Facilitates discussion of strategy and governance issues","Focuses on Board effectiveness and composition","Acts as liaison between independent directors and CEO","Advises committee chairs","Performs other Board functions as requested"] | [] | 2026 | |
| Ted Love, M.D. | Lead Independent Director; Chair | 67 | ["Former Chair, Biotechnology Innovation Organization (BIO)","Chair of BIO’s Board of Directors for a two-year term (2023-2025)","President and CEO of Global Blood Therapeutics, Inc. (June 2014 to October 2022)","Executive Vice President of research and development and technical operations at Onyx Pharmaceuticals, Inc. (February 2010 to August 2012)","President, CEO, and Chairman of Nuvelo, Inc. (2001 to January 2009)","Senior Vice President of development at Theravance, Inc. (1998 to 2001)","Experience at Genentech, Inc. in senior management positions","B.A. in molecular biology from Haverford College","M.D. from Yale Medical School","Completed residency in internal medicine and fellowship in cardiology at Massachusetts General Hospital","Experience on boards of other public healthcare companies"] | ["Nominating and Corporate Governance Committee (Chair)","Nominating and Corporate Governance Committee"] | 2026 |
| Vlad Coric | 55 | ["Leadership","Finance / Accounting","Business Strategy","Technology/Cybersecurity","Risk Management"] | [] | 2026 | |
| Vlad Coric, M.D. | Independent Director | 55 | ["Chairman and CEO, Biohaven Limited","Chief executive officer and director of Biohaven since 2015","Group director of global clinical research at Bristol-Myers Squibb Company","Associate clinical professor of psychiatry at Yale School of Medicine","Strong business expertise and experience in discovering, developing and commercializing therapies"] | ["Management Development and Compensation Committee"] | 2026 |
